Biomarker insights by Abzu.

Understand disease by revealing important disease mechanisms.

Revealing new dimensions: Biomarker insights by Abzu.

Explore all biomarker insights by Abzu.

Step into the world of biomarker insights with Abzu, where we bridge cutting-edge research of disease mechanisms with practical solutions. Here, we explore uncharted territories of the “why” behind diseases, driving innovations in diagnostics and therapeutics.

Select your favorite media.

Or simply browse all biomarker insights with Abzu.

Abzu’s explainable AI used in NASA GeneLab study to explain skin disorders in space.

Scientists at Abzu and NASA GeneLab have identified gene combinations that explain the origin of rashes astronauts develop during space missions

Abzu and NASA GeneLab study dermatological changes in spaceflight.

Abzu’s QLattice uniquely identified key “partner” genes involved in skin spaceflight response, a new discovery for how spaceflight damages skin.

Abzu identified which metabolites are present in early or late denning in bears.

Understanding how bears can hibernate without developing blood clots or muscle atrophy can help humans prepare for the future of space travel.

NASA GeneLab 2023 AWG Symposium: The year of open science.

Abzu's Jonas Elsborg presents his research with NASA GeneLab: "Elucidating dermatological changes in spaceflight with explainable AI."

Video
Biomarkers, Culture

The TOLAC project.

The TOLAC project brings data-driven insights to expectant parents at important stages of pregnancy to reduce the risk inherent in vaginal or caesarian delivery.

Abzu® selected partner for EU project Elegant North to create a new strategy for handling data on rare diseases.

To address the deficiency of treatments for rare diseases, the selected partners in project Elegant North will create a cross-border, rare disease data-sharing platform to foster cross-sector collaboration between researchers, companies, and healthcare systems.

Abzu reveals early predictive response biomarkers in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.

Stratifying patients at pretreatment by answering the question: Can we distinguish which patients will respond to OMO-103 treatment at baseline?

Abzu® reveals insights in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.

Peptomyc used the QLattice and Abzu’s expertise in patient stratification to reveal early predictive response-biomarkers to treatment with OMO-103 in metastatic patients. The analysis by the QLattice was conducted on a very small clinical trial of 22 patients.

Trustworthy data science and good clinical practice.

Good clinical practice requires responsible conduct and considerations of safety and ethics.

Intelligent Health AI

The world's leading AI-in-medicine summit series. Connecting 200,000 clinicians, technologists, and C-suite executives.

Abzu discovered key biomarkers for successful clinical trial of siRNA therapeutic.

Simple models accurately predicted and explained key biomarkers for successful clinical trial test of siRNA designed to downregulate.

Peptide drug development: Featurization and modeling of anticancer peptides.

An example of peptide drug development: Featurization and modeling using anticancer peptides.

Techtopia podcast: Dasnk AI mod brystcancer.

Abzu om Techtopia: Den kunstige intelligens skal ud af den sorte box, så vi kan forstå, hvordan den er nået til sit resultat, og hvad vi kan bruge det til.

Multi-omics analysis made easy: A breast cancer example

The QLattice, a new explainable AI algorithm, can cut through the noise of omics data sets and point to the most relevant inputs and models.

Accelerating scientific discoveries with explainable AI: A breast cancer example.

A 17 minute video about Abzu's origins and an impactful application of explainable AI in life science: diagnosing breast cancer mortality.

Event
Biomarkers, Company

TechBBQ 2021

Accelerating scientific discoveries with Abzu's explainable AI: A breast cancer example

Pioneering in novel biomarkers.

Innovative insights into disease pathways, interactions, and mechanisms.

We’re transforming the landscape of disease understanding through our specialized workflow to identify biomarkers.

We decode the complex language of diseases through our trustworthy, explainable AI, advanced analysis, and research techniques, offering a more comprehensive understanding of pathological processes.

Abzu is your partner in identifying novel biomarkers.

A cycle of discovery and validation — to realization.

Whether we start by understanding disease status from data or validating candidates through designed experiments, Abzu provides you the the insights and confidence to accelerate your R&D and discover novel biomarkers with ease.

Subscribe for
notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.